Marc and Jennifer Lipschultz Precision Immunology Institute

Precision Immunology and Experimental Medicine Trial Organization (PrIME Trials)

Science Accelerating Clinical Trials for Inflammatory Diseases

PrIME Trials build on the guiding principle of PrIISM, the Marc and Jennifer Lipschultz Precision Immunology Institute, that many inflammatory diseases arise from shared immune mechanisms and can be better understood by studying the immune system rather than individual organs.

Through an integrated clinical and translational platform, every PrIME Trial not only evaluates a promising therapy but also deepens our understanding of immune-mediated disease. The result is a continuous cycle in which clinical trials accelerate scientific discovery, and scientific discovery informs the next generation of precision immunotherapies.

Partner with PrIME Trials
Are you developing an innovative cellular or immune-engineering therapy? Explore opportunities to work with PrIME Trials to accelerate early-phase clinical trials, evaluate therapies across indications, and gain deeper insights into treatment mechanisms and responses.

About PrIME Trials
Therapies that utilize or manipulate human immune cells are changing the paradigm for the treatment of inflammatory diseases. Cell-based immunotherapies correct disease-causing cell populations rather than simply suppressing the inflammatory signals they produce. The Precision Immunology and Experimental Medicine Trial Organization (PrIME Trials) is an innovative program—independent of traditional clinical and scientific disciplines—that is shifting the focus from organ-based inflammatory diseases into a unified focus on the immune system. We are finding opportunities to test single therapeutic strategies across multiple clinical indications since many of these immune mechanisms are shared across diseases.

Drawing on Mount Sinai's established expertise in inflammatory and autoimmune diseases, including its IBD, MS, and rheumatology centers and newly launched Colton Center for Autoimmunity, PrIME Trials bring together the clinical, scientific and operational expertise needed to develop and deliver innovative clinical studies. Working with industry and academic partners, PrIME Trials provide an end-to-end platform for early-phase clinical trials of cellular and immune-engineering therapies, combining efficient trial delivery with deep immune profiling to understand how these therapies work, identify biomarkers of response, and accelerate the development of the next generation of precision immunotherapies.

Disease specialists from across Mount Sinai work together to identify the patients most likely to benefit from novel immunotherapies and to design efficient early-phase basket trials across inflammatory diseases. Every protocol is reviewed jointly by clinical investigators, immunologists, and cellular therapy specialists to maximize both clinical impact and scientific value while drawing on the regulatory and clinical expertise of the Tisch Cancer Institute Cellular Therapy Program. Learn More

Every trial is designed to optimize translational studies to facilitate a mechanistic understanding of each cellular therapy and how they lead to better patient outcomes. High-dimensional immune profiling, spatial and single-cell technologies, molecular analyses, and longitudinal clinical data are integrated to reveal how therapies reshape the immune system, identify biomarkers of response and resistance, and uncover new therapeutic targets. Through OCCAM Immune, an academic research organization within Mount Sinai, PrIME Trials provide comprehensive biospecimen processing, immune monitoring, and data integration that can also support multicenter national and international studies. Learn More

PrIME Trials provide centralized support for every stage of study delivery, including protocol development, feasibility assessment, regulatory strategy, study activation, budget management, trial coordination, and ongoing operations. By integrating experienced operational leadership with scientific and clinical teams from the outset, studies launch more efficiently while maintaining the highest standards of quality and regulatory compliance. PrIME Trials also can interface with existing clinical trial operations at Mount Sinai as a hub and spoke model to build each study specifically to the needs of the program. As such PrIME Trials are able to integrate the extensive expertise of our clinical trials organizations to ensure each study is implemented using the best resources available at Mount Sinai.

A key feature of PrIME Trials are their integration with the new Facilitated Activation and Start-up of Trials (FASTrack) program, an innovative clinical research operations initiative designed to accelerate study activation to improve the efficiency of clinical and translational research while maintaining compliance and financial integrity. In FASTrack, dedicated program managers guide clinical trials through activation milestones while coordinating and facilitating communication among investigators, research teams, regulatory offices, contracting groups and institutional stakeholders with Industry Partners.

PrIME Trials act as integrated hub for clinical, scientific, and industry leaders to evaluate and implement studies that are considered to hold the greatest promise. As a centralized, end-to-end research operations partner, PrIME Trials support every stage of study implementation—from feasibility assessments and site selection through study start-up, activation, regulatory oversight, budget and fiscal management, and ongoing study administration.

Executive Leadership

Miriam Merad, MD, PhD       
Director, Precision Immunology Institute

Louis J. Cohen, MD
Associate Professor; Gastroenterology

Rosemarie Gagliardi, EdD, MPH, CCRA
Senior Associate Dean, Collaborative Research and Partnerships

Ed Hicks, MBA
Senior Director and Administrator, Icahn School of Medicine at Mount Sinai

Stephanie Dormesy, MPH
Clinical Research Program Director (PrIMe)

Members

Clinical expertise

Cell therapy

Translational science

Are you a candidate for one of our clinical trials? Ongoing clinical trials and contact information are listed below. Learn More